Last reviewed · How we verify
Placebo of AD-224A — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo of AD-224A (Placebo of AD-224A) — Addpharma Inc.. This is a placebo, meaning it has no active therapeutic effect.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo of AD-224A TARGET | Placebo of AD-224A | Addpharma Inc. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo of AD-224A CI watch — RSS
- Placebo of AD-224A CI watch — Atom
- Placebo of AD-224A CI watch — JSON
- Placebo of AD-224A alone — RSS
Cite this brief
Drug Landscape (2026). Placebo of AD-224A — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-of-ad-224a. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab